Shanghai Junshi Biosciences Co Ltd
01877
Company Profile
Business description
Shanghai Junshi Biosciences Co Ltd is mainly engaged in innovation-driven biopharmaceutical business. The company's main products include teriprizumab injection, Etesevimab, adalimumab injection, and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases, and infectious diseases. The group’s operations are mainly located in the PRC and the United States of America.
Contact
No. 987 Cai Lun Road
Level 4, Pilot Free Trade Zone
Shanghai
CHNT: +86 2161058800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2,578
Stocks News & Analysis
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
stocks
Morningstar analyst reacts to Macquarie Group’s earnings
Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,023.30 | 56.60 | 0.63% |
| CAC 40 | 7,857.36 | 56.48 | 0.72% |
| DAX 40 | 24,217.37 | 247.01 | 1.03% |
| Dow JONES (US) | 44,632.99 | 204.57 | -0.46% |
| FTSE 100 | 9,136.32 | 54.88 | 0.60% |
| HKSE | 25,473.40 | 51.05 | -0.20% |
| NASDAQ | 21,098.29 | 80.29 | -0.38% |
| Nikkei 225 | 40,682.14 | 7.59 | 0.02% |
| NZX 50 Index | 12,961.28 | 24.87 | 0.19% |
| S&P 500 | 6,370.86 | 18.91 | -0.30% |
| S&P/ASX 200 | 8,764.10 | 59.50 | 0.68% |
| SSE Composite Index | 3,632.41 | 22.70 | 0.63% |